Low dose apixaban as secondary prophylaxis for venous thromboembolism in cancer patients
Apixaban is a treatment option for venous thromboembolism (VTE) in cancer patients. A Norwegian study investigated the efficacy and safety of apixaban 2.5 mg twice daily as prophylaxis for recurrent VTE after 6 months initial treatment with full dose apixaban. In this MEDtalk, Trine-Lise Hannevik, MD, Akershus University Hospital, Lørenskog, Norway, presents the results of the study.
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.